300 related articles for article (PubMed ID: 26026742)
1. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
3. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
4. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
5. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
[TBL] [Abstract][Full Text] [Related]
6. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.
Kusamura S; Hutanu I; Baratti D; Deraco M
J Surg Oncol; 2013 Jul; 108(1):1-8. PubMed ID: 23720095
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center.
Deraco M; Kusamura S; Laterza B; Favaro M; Fumagalli L; Costanzo P; Baratti D
In Vivo; 2006; 20(6A):773-6. PubMed ID: 17203766
[TBL] [Abstract][Full Text] [Related]
10. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
[TBL] [Abstract][Full Text] [Related]
11. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
[TBL] [Abstract][Full Text] [Related]
13. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
Di Fabio F; Aston W; Mohamed F; Chandrakumaran K; Cecil T; Moran B
Colorectal Dis; 2015 Aug; 17(8):698-703. PubMed ID: 25704482
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery with a hyperthermic intraperitoneal chemotherapy program: Safe after 40 cases, but only controlled after 140 cases.
Voron T; Eveno C; Jouvin I; Beaugerie A; Lo Dico R; Dagois S; Soyer P; Pocard M
Eur J Surg Oncol; 2015 Dec; 41(12):1671-7. PubMed ID: 26461254
[TBL] [Abstract][Full Text] [Related]
15. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
[TBL] [Abstract][Full Text] [Related]
16. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
[TBL] [Abstract][Full Text] [Related]
19. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience.
Bhatt A; Sheshadri D; Chandan G; Ramaswamy V; Pandey J; Bhorkar N; Agrawal D; Mehta S
J BUON; 2017; 22(1):251-257. PubMed ID: 28365962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
